Journal of Clinical Oncology
Articles in this Issue
Patient-reported outcome planning and reporting in CAR-T and CD3xCD20 bispecific antibody trials for relapsed/refractory lymphoma: A cross-sectional analysis (2017–2025).
e19107 Background: Patient-reported outcomes (PROs) are increasingly prioritized in lymphoma trials to contextualize benef...
Safety and feasibility of accelerated consolidative gamma knife radiotherapy following brain metastases resection.
e14020 Background: Consolidative radiotherapy is the standard of care following surgical resection of brain metastases; ho...
Influence of low-coverage whole-genome sequencing–based urinary tumor fraction and chromosomal instability on recurrence risk stratification in systemic immunotherapy-treated non–muscle–invasive bladder cancer.
4603 Background: Urinary tumor DNA (utDNA) is increasingly explored for prognostic assessment in bladder cancer, but most...
Final results of a first-in-human study of the MC1R-targeting radiopharmaceutical <sup>225</sup> actinium MTI-201 ( <sup>225</sup> Ac-MTI-201) in metastatic uveal melanoma (mUM).
3099 Background: Prognosis in mUM is poor with limited efficacy of currently available therapies. The melanocortin-1 recep...
Impact of organ-adjacent extracellular vesicle proteomics from uterine lavage on accurate detection and discrimination of ovarian cancer.
5581 Background: Survival in ovarian cancer (OvCA) exceeds 90% when disease is localized, yet most cases present at advanc...
Aspirin use and survival outcomes in endometrial cancer.
5621 Background: Given the worsening survival trends of endometrial cancer in the United States, further improvement in ad...
Implementation of <i>DPYD</i> genotyping in response to FDA black box warning: Initial experience at a comprehensive cancer center.
e15139 Background: A subset of DPYD polymorphisms contribute to poor catabolism of...
Induction failure (IF) as a prognostic marker in adult acute lymphoblastic leukemia (ALL).
6546 Background: Despite advances in the treatment of adult ALL, risk factors for IF and optimal management are poorly und...
National trends in non-melanoma skin cancer–related hospitalizations and in-hospital outcomes in the United States, 2018–2022.
e21552 Background: Non-melanoma skin cancers (NMSC) represent the most common malignancies in the United States and are pr...
HPV-stratified tissue factor expression and multi-omic correlates of overall survival after tisotumab vedotin in cervical cancer.
5537 Background: Cervical cancer (CxC) is heterogeneous, and the impact of HPV status on outcomes with tisotumab vedotin (...
A national, patient-centered AI framework for equitable oncology clinical trial access: Early outcomes from the first 10 months of ACS ACTS.
e13573 Background: Less than 10% of eligible cancer patients enroll in clinical trials (CT) due to fragmented information,...
An SMS-enhanced supportive program to improve treatment management and communication during active cancer treatment.
e13714 Background: Patients undergoing active cancer treatment have high symptom burden and psychosocial distress that oft...
Preclinical evaluation of CT03: A cardiosafe, first-in-class bifunctional MCL1 degrader for the treatment of hematological malignancies.
e15107 Background: MCL1, a crucial member of the Bcl2 family, acts as a key pro-survival factor that prevents apoptosis an...
Impact of duration of bone-targeting agent on adverse events (AEs) and skeletal-related events (SRE) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223): Real-world experience from Princess Margaret Cancer Centre (PM).
e17052 Background: Bone-targeting agents (BTAs) are guidelines-recommended to reduce SREs in patients with mCRPC and bone...
AI-assisted preoperative communication in prostate cancer: A prospective, single-blinded, randomized phase II trial.
5024 Background: To evaluate whether AI-assisted preoperative communication reduced patient anxiety, and physician workloa...
Tumor cell-intrinsic programs of metabolic adaptation and immune evasion in colorectal cancer liver metastases (CRCLMs).
3554 Background: CRCLMs account for the majority of colorectal cancer (CRC)-related mortality and represent a key site of...
Phase III study of multidisciplinary therapy combining local ablative therapy with immune-checkpoint inhibitors for patients with synchronous oligometastatic NSCLC (J-OLIGO: WJOG20924L).
TPS8667 Background: The standard of care for stage IV non-small cell lung cancer (NSCLC) patients without actionable drive...
Declined or refused?: Electronic health record documentation of patients who do not proceed with recommended care by provider characteristics.
e13725 Background: Labeling a patient as "refusing" care can be stigmatizing; alternative terms more accurately and neutra...
Predictors of real-world progression-free survival (rwPFS) in patients (pts) with epithelial ovarian cancer (EOC) treated with first-line maintenance (1LM) niraparib (nir): Post hoc analysis of the 1NSPIRE chart review study.
e17556 Background: The retrospective, US-based multicenter 1NSPIRE chart review study reported a median rwPFS of 21.7 mo i...
Early vs late survival patterns of chemoimmunotherapy compared with immune checkpoint inhibitor monotherapy in non–small cell lung cancer.
e20603 Background: Immune checkpoint inhibitors (ICIs) have improved long-term outcomes in multiple cancers, and ICI trial...
Outcomes and clinicopathological characteristics of patients with metaplastic breast cancer at the National Cancer Institute Mexico between 2016-2020.
e12747 Background: Metaplastic breast cancer is a rare histological subtype (< 1%) with dismissal prognosis and few stu...
Long-term sex-specific trends in heart, pericardial, and mediastinal tumors: A population-based analysis (1975–2022).
e22604 Background: Heart, pericardial, and mediastinal tumors are rare neoplasms with potential sex-specific disparities....
The tetravalent death receptor 5 (DR5) agonist ozekibart (INBRX-109) in conventional chondrosarcoma (CS): Secondary efficacy endpoints from the randomized, registrational, phase 2 ChonDRAgon study.
11504 Background: Clinical outcomes for unresectable/metastatic CS are poor. There are no approved therapies, and systemic...
The COMPLETE-CRC screening initiative: Increasing colonoscopy completion after positive stool-based colorectal cancer screening.
e23288 Background: Timely completion of colonoscopy after a positive colorectal cancer (CRC) screening test is essential t...
Molecular profiling and survival outcomes in colorectal cancer in Egypt: Implications for precision oncology in real-world practice.
e15703 Background: Colorectal cancer (CRC) is a molecularly heterogeneous disease, and biomarker-guided treatment has beco...